作者: P. J. Clark , A. Aghemo , E. Degasperi , E. Galmozzi , T. J. Urban
DOI: 10.1111/JVH.12113
关键词:
摘要: Anaemia frequently complicates peginterferon/ribavirin therapy for chronic hepatitis C infection. Better prediction of anaemia, ribavirin dose reduction or erythropoietin (EPO) need, may enhance patient management. Inosine triphosphatase (ITPA) genetic variants are associated with ribavirin-induced anaemia and reduction; however, their impact in real-life clinic cohorts remains to be defined. We studied 193 patients infection mixed viral genotype (genotype 1/4 n = 123, 2/3, 70) treated peginterferon/ribavirin. Patients were genotyped ITPA polymorphisms rs1127354 rs7270101 using Taqman primers. Hardy-Weinberg equilibrium was present. Estimated deficiency graded on severity (0-3, no deficiency/mild/moderate/severe, 126/40/24/3, respectively). Multivariable models tested the association at 4 weeks treatment [including decline haemoglobin (g/dL); 3 g/dL]; EPO use explored sustained response (SVR) More severe less level (P < 0.001; R2 0.34), (OR 0.42; (95% CI 0.23-0.77); P 0.005) [OR 0.53; (0.30-0.94); 0.029]. SVR [OR: 1.70; (1.02-2.83); 0.041] independently clinical covariates (adjusted 0.31). In this cohort, helped predict risk on-treatment reduction, need support SVR. For HCV regimens including peginterferon/ribavirin, testing have utility.